TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Alberg, A. J. AU - Samet, J. M. PY - 2003 DA - 2003// TI - Epidemiology of lung cancer JO - Chest VL - 123 UR - https://doi.org/10.1378/chest.123.1_suppl.21S DO - 10.1378/chest.123.1_suppl.21S ID - Alberg2003 ER - TY - JOUR AU - Pao, W. AU - Wang, T. Y. AU - Riely, G. J. AU - Miller, V. A. AU - Pan, Q. AU - Ladanyi, M. PY - 2005 DA - 2005// TI - KRAS mutations and primary resistance of lung adenocarcinomas to Gefitinib or Erlotinib JO - PLoS Med VL - 2 UR - https://doi.org/10.1371/journal.pmed.0020057 DO - 10.1371/journal.pmed.0020057 ID - Pao2005 ER - TY - JOUR AU - Miller, V. A. AU - Kris, M. G. AU - Shah, N. AU - Patel, J. AU - Azzoli, C. AU - Gomez, J. PY - 2004 DA - 2004// TI - Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.08.158 DO - 10.1200/JCO.2004.08.158 ID - Miller2004 ER - TY - JOUR AU - Travis, W. D. AU - Travis, L. B. AU - Devesa, S. S. PY - 1995 DA - 1995// TI - Lung cancer JO - Cancer VL - 75 UR - https://doi.org/3.0.CO;2-Y DO - 3.0.CO;2-Y ID - Travis1995 ER - TY - JOUR AU - Pao, W. AU - Miller, V. A. PY - 2005 DA - 2005// TI - Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.799 DO - 10.1200/JCO.2005.07.799 ID - Pao2005 ER - TY - JOUR AU - Giaccone, G. PY - 2000 DA - 2000// TI - Clinical perspectives on platinum resistance JO - Drugs VL - 59 UR - https://doi.org/10.2165/00003495-200059004-00002 DO - 10.2165/00003495-200059004-00002 ID - Giaccone2000 ER - TY - JOUR AU - Chen, D. AU - Milacic, V. AU - Frezza, M. AU - Dou, Q. P. PY - 2009 DA - 2009// TI - Metal complexes, their cellular targets and potential for cancer therapy JO - Curr Pharm Des VL - 15 UR - https://doi.org/10.2174/138161209787582183 DO - 10.2174/138161209787582183 ID - Chen2009 ER - TY - JOUR AU - Momekov, G. AU - Ferdinandov, D. AU - Bakalova, A. AU - Zaharieva, M. AU - Konstantinov, S. AU - Karaivanova, M. PY - 2006 DA - 2006// TI - In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands JO - Arch Toxicol VL - 80 UR - https://doi.org/10.1007/s00204-006-0078-0 DO - 10.1007/s00204-006-0078-0 ID - Momekov2006 ER - TY - JOUR AU - Vaupel, P. AU - Mayer, A. PY - 2007 DA - 2007// TI - Hypoxia in cancer: significance and impact on clinical outcome JO - Cancer Metastasis Rev VL - 26 UR - https://doi.org/10.1007/s10555-007-9055-1 DO - 10.1007/s10555-007-9055-1 ID - Vaupel2007 ER - TY - JOUR AU - Shannon, A. M. AU - Bouchier-Hayer, D. J. AU - Condron, C. M. AU - Toomey, D. PY - 2003 DA - 2003// TI - Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies JO - Cancer Treat Rev VL - 29 UR - https://doi.org/10.1016/S0305-7372(03)00003-3 DO - 10.1016/S0305-7372(03)00003-3 ID - Shannon2003 ER - TY - JOUR AU - Mansfield, K. D. AU - Simon, M. C. AU - Keith, B. PY - 2004 DA - 2004// TI - Hypoxic reduction in cellular glutathione levels requires mitochondrial reactive oxygen species JO - J Appl Physiol VL - 97 UR - https://doi.org/10.1152/japplphysiol.00449.2004 DO - 10.1152/japplphysiol.00449.2004 ID - Mansfield2004 ER - TY - JOUR AU - Song, X. AU - Liu, X. AU - Chi, W. AU - Liu, Y. AU - Wei, L. AU - Wang, X. PY - 2006 DA - 2006// TI - Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of Hif-1alpha gene JO - Cancer Chemother Pharmacol VL - 58 UR - https://doi.org/10.1007/s00280-006-0224-7 DO - 10.1007/s00280-006-0224-7 ID - Song2006 ER - TY - JOUR AU - Skvortsova, I. AU - Skvortsov, S. AU - Haidenberger, A. AU - Devries, A. AU - Nevinny-Stickel, M. AU - Saurer, M. PY - 2004 DA - 2004// TI - Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro JO - J Chemother VL - 16 UR - https://doi.org/10.1179/joc.2004.16.4.372 DO - 10.1179/joc.2004.16.4.372 ID - Skvortsova2004 ER - TY - JOUR AU - Wohlkoenig, C. AU - Leithner, K. AU - Deutsch, A. AU - Hrzenjak, A. AU - Olschewski, A. AU - Olschewski, H. PY - 2011 DA - 2011// TI - Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells JO - Cancer Lett VL - 308 UR - https://doi.org/10.1016/j.canlet.2011.03.014 DO - 10.1016/j.canlet.2011.03.014 ID - Wohlkoenig2011 ER - TY - JOUR AU - Florea, A. M. AU - Buesselberg, D. PY - 2011 DA - 2011// TI - Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects JO - Cancers VL - 3 UR - https://doi.org/10.3390/cancers3011351 DO - 10.3390/cancers3011351 ID - Florea2011 ER - TY - JOUR AU - Ozkaya, S. AU - Findik, S. AU - Dirican, A. AU - Atici, A. G. PY - 2012 DA - 2012// TI - Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine JO - Exp Ther Med VL - 4 ID - Ozkaya2012 ER - TY - JOUR AU - Swinson, D. E. AU - Jones, J. L. AU - Cox, G. AU - Richardson, D. AU - Harris, A. L. AU - KJ, O. ’. B. PY - 2004 DA - 2004// TI - Hypoxia-inducible factor-1 alpha in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways JO - Int J Cancer VL - 111 UR - https://doi.org/10.1002/ijc.20052 DO - 10.1002/ijc.20052 ID - Swinson2004 ER - TY - JOUR AU - Geng, H. AU - Harvey, C. T. AU - Pittsenbarger, J. AU - Liu, Q. AU - Beer, T. M. AU - Xue, C. PY - 2011 DA - 2011// TI - HDAC4 protein regulates HIF-1a protein lysine acetylation and cancer cell response to hypoxia JO - J Biol Chem VL - 286 UR - https://doi.org/10.1074/jbc.M111.257055 DO - 10.1074/jbc.M111.257055 ID - Geng2011 ER - TY - JOUR AU - Qian, D. Z. AU - Kachhap, S. K. AU - Collis, S. J. AU - Verheul, H. M. AU - Carducci, M. A. AU - Atadja, P. PY - 2006 DA - 2006// TI - Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-4598 DO - 10.1158/0008-5472.CAN-05-4598 ID - Qian2006 ER - TY - JOUR AU - Atadja, P. PY - 2009 DA - 2009// TI - Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges JO - Cancer Lett VL - 280 UR - https://doi.org/10.1016/j.canlet.2009.02.019 DO - 10.1016/j.canlet.2009.02.019 ID - Atadja2009 ER - TY - JOUR AU - Ma, Y. Y. AU - Iin, H. AU - Moh, J. S. AU - Chen, K. D. AU - Wang, I. W. AU - Ou, Y. C. PY - 2011 DA - 2011// TI - Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells JO - Taiwan J Obstet Gynecol VL - 50 UR - https://doi.org/10.1016/j.tjog.2011.01.022 DO - 10.1016/j.tjog.2011.01.022 ID - Ma2011 ER - TY - JOUR AU - Lemoine, M. AU - Derenzini, E. AU - Buglio, D. AU - Medeiros LJD, R. E. AU - Zhang, J. AU - Ji, Y. PY - 2012 DA - 2012// TI - The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-01-331421 DO - 10.1182/blood-2011-01-331421 ID - Lemoine2012 ER - TY - JOUR AU - Wang, H. AU - Cao, Q. AU - Dudek, A. Z. PY - 2012 DA - 2012// TI - Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy JO - Anticancer Res VL - 32 ID - Wang2012 ER - TY - JOUR AU - Crisanti, M. C. AU - Wallace, A. F. AU - Kapoor, V. AU - Vandermeers, F. AU - Dowling, M. L. AU - Pereira, L. P. PY - 2009 DA - 2009// TI - The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer JO - Mol Cancer Ther VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-09-0138 DO - 10.1158/1535-7163.MCT-09-0138 ID - Crisanti2009 ER - TY - JOUR AU - Zhou, Q. AU - Agoston, A. T. AU - Atadja, P. AU - Nelson, W. G. AU - Davidson, N. E. PY - 2008 DA - 2008// TI - Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells JO - Mol Cancer Res VL - 6 UR - https://doi.org/10.1158/1541-7786.MCR-07-0330 DO - 10.1158/1541-7786.MCR-07-0330 ID - Zhou2008 ER - TY - JOUR AU - Kauh, J. AU - Fan, S. AU - Xia, M. AU - Yue, P. AU - Yang, F. R. AU - Sun, S. Y. PY - 2010 DA - 2010// TI - c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589 JO - PLoS ONE VL - 5 UR - https://doi.org/10.1371/journal.pone.0010376 DO - 10.1371/journal.pone.0010376 ID - Kauh2010 ER - TY - JOUR AU - Berndtsson MH, M. AU - Panaretakis, T. AU - Havelka, A. M. AU - Shoshan, M. C. AU - Linder, S. PY - 2007 DA - 2007// TI - Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA JO - Int J Cancer VL - 120 UR - https://doi.org/10.1002/ijc.22132 DO - 10.1002/ijc.22132 ID - Berndtsson MH2007 ER - TY - JOUR AU - Michaels, J. AU - Vitale, I. AU - Galluzzi, L. AU - Adam, J. AU - Olaussen, K. A. AU - Kepp, O. PY - 2013 DA - 2013// TI - Cisplatin resistance associated with PARP hyperactivation JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3000 DO - 10.1158/0008-5472.CAN-12-3000 ID - Michaels2013 ER - TY - JOUR AU - Bunn, P. A. AU - Kelly, K. PY - 1998 DA - 1998// TI - New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions JO - Clin Cancer Res VL - 34 ID - Bunn1998 ER - TY - JOUR AU - Marek, L. AU - Hamacher, A. AU - Hansen, F. AU - Kuna, K. AU - Gohlke, H. AU - Kassack, M. PY - 2013 DA - 2013// TI - Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells JO - J Med Chem VL - 56 UR - https://doi.org/10.1021/jm301254q DO - 10.1021/jm301254q ID - Marek2013 ER - TY - JOUR AU - Okudela, K. AU - Mitsui, H. AU - Suzuki, T. AU - Woo, T. AU - Tateishi, Y. AU - Umeda, S. PY - 2014 DA - 2014// TI - Expression of HDAC9 in lung cancer – potential role in lung carcinogenesis JO - Int J Clin Exp Pathol VL - 7 ID - Okudela2014 ER - TY - JOUR AU - Perez, R. P. PY - 1998 DA - 1998// TI - Cellular and molecular determinants of cisplatin resistance JO - Eur J Cancer VL - 34 UR - https://doi.org/10.1016/S0959-8049(98)00227-5 DO - 10.1016/S0959-8049(98)00227-5 ID - Perez1998 ER - TY - JOUR AU - Galluzzi, L. AU - Senovilla, L. AU - Vitale, I. AU - Michels, J. AU - Martins, I. AU - Kepp, O. PY - 2012 DA - 2012// TI - Molecular mechanisms of cisplatin resistance JO - Oncogene VL - 31 UR - https://doi.org/10.1038/onc.2011.384 DO - 10.1038/onc.2011.384 ID - Galluzzi2012 ER - TY - JOUR AU - Cea, M. AU - Cagnetta, A. AU - Gobbi, M. AU - Patrone, F. AU - Richardson, P. G. AU - Hideshima, T. PY - 2013 DA - 2013// TI - New insights into the treatment of multiple myeloma with histone deacetylase inhibitors JO - Curr Pharm Des VL - 19 UR - https://doi.org/10.2174/138161213804581945 DO - 10.2174/138161213804581945 ID - Cea2013 ER - TY - JOUR AU - Wagner, J. M. AU - Hackanson, B. AU - Luebbert, M. AU - Jung, M. PY - 2010 DA - 2010// TI - Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy JO - Clin Epigenetics VL - 1 UR - https://doi.org/10.1007/s13148-010-0012-4 DO - 10.1007/s13148-010-0012-4 ID - Wagner2010 ER - TY - JOUR AU - Ocio, E. M. AU - Vilanova, D. AU - Atadja, P. AU - Maiso, P. AU - Crusoe, E. AU - Fernandez-Lazaro, D. PY - 2010 DA - 2010// TI - In vitro and in vivo rationale for the triple combina-tion of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.015495 DO - 10.3324/haematol.2009.015495 ID - Ocio2010 ER - TY - JOUR AU - Fiskus, W. AU - Rao, R. AU - Balusu, R. AU - Ganguly, S. AU - Tao, J. AU - Sotomayor, E. PY - 2012 DA - 2012// TI - Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0873 DO - 10.1158/1078-0432.CCR-12-0873 ID - Fiskus2012 ER - TY - JOUR AU - Lee, S. C. AU - Cheong, H. J. AU - Kim, S. J. AU - Yoon, J. AU - Kim, H. J. AU - Kim, K. H. PY - 2011 DA - 2011// TI - Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines JO - Anticancer Res VL - 31 ID - Lee2011 ER - TY - JOUR AU - Sunaga, N. AU - Shames, D. S. AU - Girard, L. P. AU - Larsen JE, M. AU - Imai, H. AU - Soh, J. PY - 2011 DA - 2011// TI - Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-10-0750 DO - 10.1158/1535-7163.MCT-10-0750 ID - Sunaga2011 ER - TY - JOUR AU - Richon, V. M. AU - Sandhoff, T. W. AU - Rifkind, R. A. AU - Marks, P. A. PY - 2000 DA - 2000// TI - Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation JO - Proc Natl Acad Sci U S A VL - 97 UR - https://doi.org/10.1073/pnas.180316197 DO - 10.1073/pnas.180316197 ID - Richon2000 ER - TY - JOUR AU - Dempke, W. AU - Voigt, W. AU - Grothey, A. AU - Hill, B. AU - Schmoll, H. J. PY - 2000 DA - 2000// TI - Cisplatin resistance and oncogenes - a review JO - Anticancer Drugs VL - 11 UR - https://doi.org/10.1097/00001813-200004000-00001 DO - 10.1097/00001813-200004000-00001 ID - Dempke2000 ER - TY - JOUR AU - Sonnemann, J. AU - Marx, C. AU - Becker, S. AU - Wittig, S. AU - Palani, C. D. AU - Kraemer, O. H. PY - 2013 DA - 2013// TI - p53-dependent and ßp53-independent anticancer effects of different histone deacetylase inhibitors JO - Br J Cancer VL - 110 UR - https://doi.org/10.1038/bjc.2013.742 DO - 10.1038/bjc.2013.742 ID - Sonnemann2013 ER - TY - JOUR AU - Burgess, A. AU - Ruefli, A. AU - Beamish, H. AU - Warrener, R. AU - Sunders, N. AU - Johnstone, R. PY - 2004 DA - 2004// TI - Histone deacetylase inhibitors specifically kill nonproliferating tumour cells JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207893 DO - 10.1038/sj.onc.1207893 ID - Burgess2004 ER - TY - JOUR AU - Minucci, S. AU - Pelicci, P. G. PY - 2006 DA - 2006// TI - Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1779 DO - 10.1038/nrc1779 ID - Minucci2006 ER - TY - JOUR AU - Prystowsky, M. B. AU - Adomako, A. AU - Smith, R. V. AU - Kawachi, N. AU - McKimpson, W. AU - Atadja, P. PY - 2009 DA - 2009// TI - The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines JO - J Pathol VL - 218 UR - https://doi.org/10.1002/path.2554 DO - 10.1002/path.2554 ID - Prystowsky2009 ER - TY - JOUR AU - Ozaki, K. AU - Kishikawa, F. AU - Tanaka, M. AU - Sakamoto, T. AU - Tanimura, S. AU - Kohno, M. PY - 2008 DA - 2008// TI - Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs JO - Cancer Sci VL - 99 UR - https://doi.org/10.1111/j.1349-7006.2007.00669.x DO - 10.1111/j.1349-7006.2007.00669.x ID - Ozaki2008 ER - TY - JOUR AU - Iida, Y. AU - Aoki, K. AU - Asakura, T. AU - Ueda, K. AU - Yanaihara, N. AU - KTkakura, S. PY - 2012 DA - 2012// TI - Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma JO - Int J Oncol VL - 40 ID - Iida2012 ER - TY - JOUR AU - Bohonowych, J. E. AU - Peng, S. AU - Gopal, U. AU - Hance, M. W. AU - Wing, S. B. AU - Argraves, K. M. PY - 2011 DA - 2011// TI - Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-520 DO - 10.1186/1471-2407-11-520 ID - Bohonowych2011 ER - TY - JOUR AU - Stronach, E. A. AU - Alfraidi AR, N. AU - Datler, C. AU - Studd, J. B. AU - Agarwal, R. AU - Guney, T. G. PY - 2011 DA - 2011// TI - HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-4111 DO - 10.1158/0008-5472.CAN-10-4111 ID - Stronach2011 ER - TY - JOUR AU - De Cecco, L. AU - Berardi, M. AU - Sommariva, M. AU - Cataldo, A. AU - Canevari, S. D. M. AU - Iorio, M. V. PY - 2013 DA - 2013// TI - Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation JO - PLoS ONE VL - 8 UR - https://doi.org/10.1371/journal.pone.0058849 DO - 10.1371/journal.pone.0058849 ID - De Cecco2013 ER - TY - JOUR AU - Greco, W. R. AU - Bravo, G. AU - Persons, J. C. PY - 1995 DA - 1995// TI - The search for synergy: a critical review from response surface perspective JO - Pharmacol Rev VL - 47 ID - Greco1995 ER -